IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
iBio, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 28, 2026
$0.76−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0899 (−10.58%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
iBio, Inc. saw revenue fall 75.0% to $100.00K over the twelve months to Jun 30, 2026. Free cash flow was -$23.80M.
Revenue
$100.00K
-75.0% vs. a year earlier
Operating income
-$35.14M
TTM Q4 2026
Free cash flow
-$23.80M
TTM Q4 2026
EPS, diluted
-$0.32
TTM Q4 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $110.48M
- P/E ratio
- –
- Price to sales
- 1104.84
- Price to book
- 1.29
- Dividend yield
- –
- Free cash flow yield
- -21.54%
Fundamentals
- Revenue
- $100.00K
- Net income
- -$33.04M
- EPS, diluted
- -$0.32
- Free cash flow
- -$23.80M
- Book value per share
- $0.59
- Diluted shares
- 145M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$100.00K-75.0% YoY
Gross profit
–
Operating income
-$35.14M
Net income
-$33.04M
EPS, diluted
-$0.32
Free cash flow
-$23.80M
Reported period